Sandoz stock: Ranluspec launch expands European eye-care portfolio
Published on 11/13/2026 at 18:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRanluspec broadens European reach
- Sandoz is commercialising the ranibizumab biosimilar across the European Union except Germany.
- The product adds treatment options for several retinal diseases and supports Sandoz's ophthalmology portfolio.
- The launch is presented as an early step toward the Bio100 ambition of more than 100 biosimilars by 2040.
Sandoz expanded its ophthalmology portfolio on November 12 with the European launch of Ranluspec, a ranibizumab biosimilar for patients with retinal diseases. The company described the product as an early step toward its Bio100 ambition and said the launch supports its broader biosimilars strategy, according to a Sandoz media release.
New treatment option for retinal disease
Ranluspec was approved by the European Commission in February 2026. Sandoz says the medicine has equivalent efficacy and comparable safety to Lucentis, its reference medicine.
The product is indicated for several conditions, including neovascular, or wet, age-related macular degeneration, diabetic macular oedema, proliferative diabetic retinopathy, macular oedema following retinal vein occlusion and choroidal neovascularisation. Ranluspec is developed, manufactured and registered by Lupin under a commercial partnership with Sandoz.
European rights exclude Germany
Sandoz holds exclusive commercialisation rights for Ranluspec across the European Union except Germany, with semi-exclusive rights in France. In Germany, the company markets Epruvy, another ranibizumab product, under a separate agreement.
The launch strengthens Sandoz's position in ophthalmology alongside Afqlir in Europe and Cimerli in the United States. Management also links the move to its Bio100 goal of building a portfolio of more than 100 biosimilars by 2040.
Share price context
Sandoz stock traded at 91.44 euros on Lang & Schwarz at 18:00 CET on Friday, November 13.
Sandoz Group AG
- ISIN: CH1243598427
- Share price: 91.44 euros on Lang & Schwarz at 18:00 CET on November 13, 2026
- Ranluspec: Ranibizumab biosimilar for retinal diseases
- Commercial territory: European Union except Germany
European pharmaceutical stocks remain part of the broader market setting tracked in Current market reports.
More news and analyses on Sandoz stock.
